14/03/2026
Multiple sclerosis affects over 130,000 people in the UK, and many are searching for treatments that go beyond standard disease-modifying therapies. Low Dose Naltrexone (LDN) is emerging as a compelling option backed by growing clinical evidence.
LDN works by enhancing endogenous opioid production and modulating immune response—addressing the neuroinflammation at the heart of MS. Research shows LDN may reduce relapse rates, slow progression, and improve quality of life without the side effect burden of conventional immunosuppressants.
What makes LDN different? It's affordable, well-tolerated, and works synergistically with existing MS treatments. Patients report improvements in fatigue, pain, and mobility within weeks of starting a proper titration protocol.
The evidence is compelling. Studies demonstrate LDN's role in TLR4 antagonism, reducing pro-inflammatory cytokines (TNF-α, IL-6), and promoting neuroprotection. For MS patients seeking a gentler, evidence-based approach, LDN deserves serious consideration.
Ready to explore LDN for MS? Read our full clinical guide and discover how this underrated treatment is changing lives.
👉 https://medicalmojo.co.uk/the-evidence-for-low-dose-naltrexone-ldn-use-for-multiple-sclerosis/